Recursion Pharmaceuticals, Inc. (RXRX)
NASDAQ: RXRX · Real-Time Price · USD
6.55
-0.09 (-1.36%)
Nov 5, 2024, 11:14 AM EST - Market open
Recursion Pharmaceuticals Employees
Recursion Pharmaceuticals had 500 employees as of December 31, 2023. The number of employees did not change compared to the previous year.
Employees
500
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$99,270
Profits / Employee
-$749,852
Market Cap
1.84B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 500 | 0 | - |
Dec 31, 2022 | 500 | 100 | 25.00% |
Dec 31, 2021 | 400 | 69 | 20.85% |
Dec 31, 2020 | 331 | 131 | 65.50% |
Dec 31, 2019 | 200 | - | - |
Related Stocks
Company Name | Employees |
---|---|
National HealthCare | 13,123 |
Patterson Companies | 7,600 |
NeoGenomics | 2,100 |
NovoCure | 1,453 |
Galapagos NV | 1,123 |
BioCryst Pharmaceuticals | 536 |
Arvinas | 445 |
Beam Therapeutics | 436 |
RXRX News
- 6 days ago - Recursion to Report Third Quarter 2024 Business Updates and Financial Results on November 6th - GlobeNewsWire
- 14 days ago - Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection - GlobeNewsWire
- 4 weeks ago - Buying Opportunities In Biotech And Pharma With Bhavneesh Sharma - Seeking Alpha
- 4 weeks ago - Recursion gets FDA approval to begin phase 1 trials of AI-discovered cancer treatment - CNBC
- 4 weeks ago - Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma - GlobeNewsWire
- 2 months ago - Recursion: Path Forward For REC-994 Remains Despite Mixed Response - Seeking Alpha
- 2 months ago - Recursion's blood vessel disorder drug meets main goal in mid-stage study - Reuters
- 3 months ago - Recursion Pharmaceuticals, Inc. (RXRX) Q2 2024 Earnings Call Transcript - Seeking Alpha